Ladarixin, an inhibitor of IL ‐8 receptors CXCR1 and CXCR2 , in new‐onset type 1 diabetes: a multicenter, randomized, double‐blind, placebo‐controlled trial
Diabetes, Obesity and Metabolism（2022）
Key words
diabetes,inhibitor
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined